Morgan, R.J., Synold, T.W., Carr, B.I., Doroshow, J.H., Womack, E.P., Shibata, S., Somlo, G., Raschko, J.W., Leong, L., McNamara, M., Chow, W., Tetef, M.L., Margolin, K., Akman, S., and Longmate, J. Continuous infusion prochlorperazine: Pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy Cancer Chemo. Pharmacol. 47:327-332, 2001.
Tetef, M.L., Synold, T.W., Chow, W., Leong, L., Margolin, K., Morgan, R., Raschko, J., Shibata, S., Somlo, G., Yen, Y., Groshen, S., Johnson, K., Lenz, H.-J., Gandara, D. and Doroshow, J.H. Phase I trial of 96-hour continuous infusionof dexrazoxane in patients with advanced malignancies. Clin. Cancer Res. 7: 1569-1576, 2001.
Somlo, G., Doroshow, J.H., Ahn, C., Chow, W., Hamasaki, V., Leong, L., Margolin, K., Morgan, R., Raschko, J., Shibata, S., O'Donnell, M., Smith, E., Tetef, M., Forman, S., Yen, Y., Molina, A., Sniecinski, I. Tandem cycle of high-dose melphalan and cisplatin with peripheral stem cell rescue in patients with breast cancer and other malignancies. Biol. Blood Marrow Transplant 7: 284-293, 2001.
Somlo, G., Doroshow, J.H., Synold, T., Longmate, J., Reardon, D., Chow, W., Forman, S.J., Leong, L.A., Margolin, K.A., Morgan Jr., R.J., Raschko, J.W., Shibata, S., Tetef, M.L., Yen, Y., Kogut, N., Schriber, J., and Alvarnas, J. High-dose paclitaxel in combination with doxorubicin, cyclophosphamide, and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: Toxicity profile relationship to paclitaxel, pharmacokinetics and short-term outcome. Brit. J. Cancer 84 (12): 1591-1598, 2001
Morgan, R.J., Doroshow, J.H., Leong, L., Schriber, J., Shibata, S., Forman, S., Hamasaki, V., Margolin, K., Somlo, G., Alvarnas, J., McNamara, M., Longmate, J., Raschko, J., Chow, W., Vasilev, S., McGonigle, K. and Yen, Y. Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclosphosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. Bone Marrow Transplant. 28 (9): 859-863, 2001.
Yen, Y., Doroshow, J.H., Chow, W., Leong, L., Margolin, K., Morgan, R., Raschko, J., Shibata, S., Somlo, G., Twardowski, P., Frankel, P., Longmate, J., Synold, T. and Newman, E. Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea (HU) in combination with gemcitabine (Gem): A California Cancer Consortium Trial. Cancer Chemother. Pharmacol 50: 353-359, 2002.
Somlo, G., Simpson, J.F., Frankel, P., Chow, W., Leong, L., Margolin, K., Morgan, R. Jr., Raschko, J., Shibata, S., Forman, S., Kogut, N., McNamara, M., Molina, A., Somlo, E. and Doroshow, J.H. Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Brit. J. Cancer 87(3): 281-288, 2002.
Schwarz, R.E., Smith, D.D., Keny, H., Ikle, D.N., Shibata, S.I., Chu, D.Z., and Pezner, R.D. Impact of intraoperative radiation on postoperative and disease-specific outcome after pancreatoduodenectomy for adenocarcinoma: a propensity score analysis. Amer. J. Clin. Oncol. 26: 16-21, 2003.
Morgan, R.J., Doroshow, J.H., Synold, T., Lim, D., Shibata, S., Margolin, K., Schwarz, R., Leong, L., Somlo, G., Twardowski, P., Yen, Y., Chow, W., Lin, P., Paz, B., Chu, D., Frankel, P., and Stalter, S. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: Dose-limiting toxicity and pharmacokinetics. Clin. Cancer Res. 9: 5896-5901, 2003.
Wong, J.Y.C., Shibata, S., Williams, L.E., Kwok, C.S., Liu, A., Chu, D. Z., Yamauchi, D.M., Wilczynski, S., Ikle, D.N., Wu, A.M., Yazaki, P.J., Shively, J.E., Doroshow, J.H., and Raubitschek, A.A. A phse I trial of Y 90-anti-carcinoembryonic antigen chimeric, T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin. Cancer Res. 9: 5842-5852, 2003.
Openshaw, H., Beamon, K., Synold, T.W., Longmate, J., Slatkin, N.E., Doroshow, J.H., Forman, S., Margolin, K., Morgan, R., Shibata, S., and Somlo, G. Neurophysiologivcal study of peripheral neuropathy after high-dose paclitaxel: Lack of neuroprotective effect of amifostine. Clin. Cancer Res. 10: 461-467, 2004.
Somlo, G., Frankel, P., Chow, W., Leong, L., Margolin, K., Morgan, Jr., R., Shibata, S., Chu, P., Forman, S., Lim, D., Twardowski, P., Weitzel, J., Alvarnas, J., Kogut, N., Schriber, J., Fermin, E., Damon, L. and Doroshow, J.H. Prognostic indicators and survial in 120 patients with stage IIIB inflammatory breast carcinoma following dose-intense chemotherapy. J. Clin. Oncol. 22: 1839-1848, 2004.
Shibata, S.I, Lin, S., Doroshow, J.H., Pezner, R., Chow, W., Leong, L.A., Margolin, K.A., McNamara, M.V., Morgan, R.J. Jr., Raschko, J.W., Somlo, G., Tetef, M.L., Yen, Y, Synold, T.W., Chu, D., Wagman, L., Vora, N., Carroll, M., Lee, S. and Longmate, J. Pilot Study of intraoperative and external beam radiation therapy combined with continuous infusion 5-fluorouracil in locally advanced gastrointestinal malignancies. Eur. J. Surg. Oncol. 30: 650-657, 2004.
Chow, W.A., Synold, T.W., Tetef, M.L., Longmate, J., Fankel, P., Lawrence, J., Al-Kadhimi, Z., Leong, L., Lim, D., Margolin, K., Morgan, R.J., Jr., Raschko, J., Shibata, S., Somlo, G., Twardowski, P., Yen, Y., and Doroshow, J.H. Feasibility study of concurrent infusional dexrazoxane and dose-intensive doxorubicin administered over 96 hours for the treatment of advanced malignancies. Cancer Chemother. Pharmacol. 54: 241-248, 2004.
Morgan, R.J., Jr., Synold, T.W., Gandara, D., Muggia, F., Scudder, S., Reed, E., Margolin, K., Raschko, J., Leong, L., Shibata, S., Tetef, M., Vasilev, S., McGonigle, K., Longmate, J., Yen, Y., Chow, W., Somlo, G., Carroll, M., and Doroshow, J.H. Phase II trial of carboplatin and infusional cyclosporine in recurrent ovarian cancer. Cancer Chemother. Pharmacol. 54: 283-289, 2004.
Openshaw, H., Beamon, K., Synold, T.W., Longmate, J., Slatkin, N.E., Doroshow, J.H., Forman, S., Margolin, K., Morgan, R., Shibata, S., and Somlo, G. The effect of height on paclitaxel nerve damage. J. Neurooncology 74: 207-210, 2005.
Morgan, R.J., Jr., Synold, T.W., Gandara, D., Muggia, F., Scudder, S., Reed, E., Margolin, K., Raschko, J., Leong, L., Shibata, S., Tetef, M., Vasilev, S., McGonigle, K., Longmate, J., Yen, Y., Chow, W., Somlo, G., Carroll, M., Doroshow, J.H. Phase I trial of tamoxifen, carboplatin, and topotecan in the treatment of recurrent or refractory brain or spinal cord tumors. Neurooncology, in press, 2005
This is a partial list. Full list of publications available upon request. Last updated: 07/08.
